Targeting inflammasomes: A possible therapeutic approach for periodontal disease (Review)

Rana,Anju; Kaur,Arundeep; Faraz,Farrukh; Tandon,Shruti

doi:10.3892/wasj.2021.121

Targeting inflammasomes: A possible therapeutic approach for periodontal disease (Review)

Authors:
- Anju Rana
- Arundeep Kaur
- Farrukh Faraz
- Shruti Tandon
View Affiliations

Affiliations: Department of Periodontics, Maulana Azad Institute of Dental Sciences, New Delhi 110002, India
Published online on: August 17, 2021 https://doi.org/10.3892/wasj.2021.121
Article Number: 50
Copyright: © Rana et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Inflammasomes are cytosolic multimeric protein complexes that typically comprise a sensor, an adaptor and the zymogen, procaspase‑1. Inflammasomes are a central hub for signaling and the regulation of innate immunity. An inflammasome assembles in response to a diverse range of pathogen‑associated molecular patterns or danger‑associated molecular patterns. Inflammasomes further induce the maturation of interleukin (IL)‑1β and 18 through the proteolytic cleavage of pro‑IL‑1β and pro‑IL‑18. A number of previous studies have highlighted the importance of the appropriate activation of the inflammasome in homeostasis and in the pathogenesis of periodontal disease. Inflammasomes function as a homeostatic checkpoint to regulate the extent of inflammation in health and disease. Thus, further research is required to uncover the modulators and regulators of the inflammasome assembly. The enhanced knowledge of various strategies which may be used to regulate an excessive inflammatory response at the cellular and molecular level may lead to the development of more effective strategies for the treatment and prevention of periodontal disease, as well as its associated systemic diseases.

View Figures

View References

1	Papapanou PN, Sanz M, Buduneli N, Dietrich T, Feres M, Fine DH, Flemmig TF, Garcia R, Giannobile WV, Graziani F, et al: Periodontitis: Consensus report of workgroup 2 of the 2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions. J Periodontol. 89 (Suppl 1):S173–S182. 2018.PubMed/NCBI View Article : Google Scholar
2	Oates TW, Graves DT and Cochran DL: Clinical, radiographic and biochemical assessment of IL-1/TNF-alpha antagonist inhibition of bone loss in experimental periodontitis. J Clin Periodontol. 29:137–143. 2002.PubMed/NCBI View Article : Google Scholar
3	Jandinski JJ, Stashenko P, Feder LS, Leung CC, Peros WJ, Rynar JE and Deasy MJ: Localization of interleukin-1 beta in human periodontal tissue. J Periodontol. 62:36–43. 1991.PubMed/NCBI View Article : Google Scholar
4	Kinane DF, Winstanley FP, Adonogianaki E and Moughal NA: Bioassay of interleukin 1 (IL-1) in human gingival crevicular fluid during experimental gingivitis. Arch Oral Biol. 37:153–156. 1992.PubMed/NCBI View Article : Google Scholar
5	Kornman KS, Crane A, Wang HY, di Giovine FS, Newman MG, Pirk FW, Wilson TG Jr, Higginbottom FL and Duff GW: The interleukin-1 genotype as a severity factor in adult periodontal disease. J Clin Periodontol. 24:72–77. 1997.PubMed/NCBI View Article : Google Scholar
6	Lopez-Castejon G and Brough D: Understanding the mechanism of IL-1β secretion. Cytokine Growth Factor Rev. 22:189–195. 2011.PubMed/NCBI View Article : Google Scholar
7	Marchesan JT, Girnary MS, Moss K, Monaghan ET, Egnatz GJ, Jiao Y, Zhang S, Beck J and Swanson KV: Role of inflammasomes in the pathogenesis of periodontal disease and therapeutics. Periodontol 2000. 82:93–114. 2020.PubMed/NCBI View Article : Google Scholar
8	Pettersson M, Kelk P, Belibasakis GN, Bylund D, Molin Thorén M and Johansson A: Titanium ions form particles that activate and execute interleukin-1β release from lipopolysaccharide-primed macrophages. J Periodontal Res. 52:21–32. 2017.PubMed/NCBI View Article : Google Scholar
9	Martinon F, Burns K and Tschopp J: The inflammasome: A molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell. 10:417–426. 2002.PubMed/NCBI View Article : Google Scholar
10	Bostanci N, Emingil G, Saygan B, Turkoglu O, Atilla G, Curtis MA and Belibasakis GN: Expression and regulation of the NALP3 inflammasome complex in periodontal diseases. Clin Exp Immunol. 157:415–422. 2009.PubMed/NCBI View Article : Google Scholar
11	Park E, Na HS, Song YR, Shin SY, Kim YM and Chung J: Activation of NLRP3 and AIM2 inflammasomes by Porphyromonas gingivalis infection. Infect Immun. 82:112–123. 2014.PubMed/NCBI View Article : Google Scholar
12	Aral K, Berdeli E, Cooper PR, Milward MR, Kapila Y, Karadede Ünal B, Aral CA and Berdeli A: Differential expression of inflammasome regulatory transcripts in periodontal disease. J Periodontol. 91:606–616. 2020.PubMed/NCBI View Article : Google Scholar
13	Shibata K: Historical aspects of studies on roles of the inflammasome in the pathogenesis of periodontal diseases. Mol Oral Microbiol. 33:203–211. 2018.PubMed/NCBI View Article : Google Scholar
14	Aral K, Milward MR, Kapila Y, Berdeli A and Cooper PR: Inflammasomes and their regulation in periodontal disease: A review. J Periodontal Res. 55:473–487. 2020.PubMed/NCBI View Article : Google Scholar
15	Strowig T, Henao-Mejia J, Elinav E and Flavell R: Inflammasomes in health and disease. Nature. 481:278–286. 2012.PubMed/NCBI View Article : Google Scholar
16	Zahid A, Li B, Kombe AJK, Jin T and Tao J: Pharmacological Inhibitors of the NLRP3 Inflammasome. Front Immunol. 10(2538)2019.PubMed/NCBI View Article : Google Scholar
17	Rathinam VA and Fitzgerald KA: Inflammasome complexes: Emerging mechanisms and effector functions. Cell. 165:792–800. 2016.PubMed/NCBI View Article : Google Scholar
18	Guo H, Callaway JB and Ting JP: Inflammasomes: Mechanism of action, role in disease, and therapeutics. Nat Med. 21:677–687. 2015.PubMed/NCBI View Article : Google Scholar
19	Zhang Y, Dong Z and Song W: NLRP3 inflammasome as a novel therapeutic target for Alzheimer's disease. Signal Transduct Target Ther. 5(37)2020.PubMed/NCBI View Article : Google Scholar
20	Delaleu N and Bickel M: Interleukin-1 beta and interleukin-18: Regulation and activity in local inflammation. Periodontol 2000. 35:42–52. 2004.PubMed/NCBI View Article : Google Scholar
21	Kim S, Park MH, Song YR, Na HS and Chung J: Aggregatibacter actinomycetemcomitans-induced AIM2 inflammasome activation is suppressed by xylitol in differentiated THP-1 macrophages. J Periodontol. 87:e116–e126. 2016.PubMed/NCBI View Article : Google Scholar
22	Yamaguchi Y, Kurita-Ochiai T, Kobayashi R, Suzuki T and Ando T: Regulation of the NLRP3 inflammasome in Porphyromonas gingivalis-accelerated periodontal disease. Inflamm Res. 66:59–65. 2017.PubMed/NCBI View Article : Google Scholar
23	Isaza-Guzmán DM, Medina-Piedrahíta VM, Gutiérrez-Henao C and Tobón-Arroyave SI: Salivary Levels of NLRP3 Inflammasome-Related Proteins as Potential Biomarkers of Periodontal Clinical Status. J Periodontol. 88:1329–1338. 2017.PubMed/NCBI View Article : Google Scholar
24	Higuchi K, Ziamuddin SM, Yamashita Y, Ozaki Y and Yoshimura A: Initial periodontal treatment affects nucleotide-binding domain leucine-rich repeat-containing protein 3 inflammasome priming in peripheral blood mononuclear cells. Arch Oral Biol. 110(104625)2019.PubMed/NCBI View Article : Google Scholar
25	Yamaguchi Y, Kurita-Ochiai T, Kobayashi R, Suzuki T and Ando T: Activation of the NLRP3 inflammasome in Porphyromonas gingivalis-accelerated atherosclerosis. Pathog Dis. 73(ftv011)2015.PubMed/NCBI View Article : Google Scholar
26	Mangan MSJ, Olhava EJ, Roush WR, Seidel HM, Glick GD and Latz E: Targeting the NLRP3 inflammasome in inflammatory diseases. Nat Rev Drug Discov. 17(688)2018.PubMed/NCBI View Article : Google Scholar : Erratum for: Nat Rev Drug Discov 17: 588-606, 2018.
27	Van Dyke TE: Pro-resolving mediators in the regulation of periodontal disease. Mol Aspects Med. 58:21–36. 2017.PubMed/NCBI View Article : Google Scholar
28	Chapple IL: Reactive oxygen species and antioxidants in inflammatory diseases. J Clin Periodontol. 24:287–296. 1997.PubMed/NCBI View Article : Google Scholar
29	Brock GR, Butterworth CJ, Matthews JB and Chapple IL: Local and systemic total antioxidant capacity in periodontitis and health. J Clin Periodontol. 31:515–521. 2004.PubMed/NCBI View Article : Google Scholar
30	So AK and Martinon F: Inflammation in gout: Mechanisms and therapeutic targets. Nat Rev Rheumatol. 13:639–647. 2017.PubMed/NCBI View Article : Google Scholar
31	Favus MJ and Coe FL: The effects of allopurinol treatment on stone formation on hyperuricosuric calcium oxalate stone-formers. Scand J Urol Nephrol Suppl. 53:265–271. 1980.PubMed/NCBI
32	Becker MA, MacDonald PA, Hunt BJ and Jackson RL: Diabetes and gout: Efficacy and safety of febuxostat and allopurinol. Diabetes Obes Metab. 15:1049–1055. 2013.PubMed/NCBI View Article : Google Scholar
33	Szeto HH: First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. Br J Pharmacol. 171:2029–2050. 2014.PubMed/NCBI View Article : Google Scholar
34	Lynch DR and Farmer G: Mitochondrial and metabolic dysfunction in Friedreich ataxia: Update on pathophysiological relevance and clinical interventions. Neuronal Signal. 5(NS20200093)2021.PubMed/NCBI View Article : Google Scholar
35	Mehmel M, Jovanović N and Spitz U: Nicotinamide Riboside-The Current State of Research and Therapeutic Uses. Nutrients. 12(1616)2020.PubMed/NCBI View Article : Google Scholar
36	Daubert MA, Yow E, Dunn G, Marchev S, Barnhart H, Douglas PS, O'Connor C, Goldstein S, Udelson JE and Sabbah HN: Novel mitochondria-targeting peptide in heart failure treatment: A randomized, placebo-controlled trial of elamipretide. Circ Heart Fail. 10(e004389)2017.PubMed/NCBI View Article : Google Scholar
37	Cornelis S, Kersse K, Festjens N, Lamkanfi M and Vandenabeele P: Inflammatory caspases: Targets for novel therapies. Curr Pharm Des. 13:367–385. 2007.PubMed/NCBI View Article : Google Scholar
38	Barreyro FJ, Holod S, Finocchietto PV, Camino AM, Aquino JB, Avagnina A, Carreras MC, Poderoso JJ and Gores GJ: The pan-caspase inhibitor Emricasan (IDN-6556) decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis. Liver Int. 35:953–966. 2015.PubMed/NCBI View Article : Google Scholar
39	Wannamaker W, Davies R, Namchuk M, Pollard J, Ford P, Ku G, Decker C, Charifson P, Weber P, Germann UA, et al: (S)-1-((S)-2-{[1-(4-amino-3-chloro-phenyl)-methanoyl]-amino}-3,3-dimethyl-butanoyl)-pyrrolidine-2-carboxylic acid ((2R,3S)-2-ethoxy-5-oxo-tetrahydro-furan-3-yl)-amide (VX-765), an orally available selective interleukin (IL)-converting enzyme/caspase-1 inhibitor, exhibits potent anti-inflammatory activities by inhibiting the release of IL-1beta and IL-18. J Pharmacol Exp Ther. 321:509–516. 2007.PubMed/NCBI View Article : Google Scholar
40	de Torre-Minguela C, Mesa Del Castillo P and Pelegrín P: The NLRP3 and pyrin inflammasomes: Implications in the pathophysiology of autoinflammatory diseases. Front Immunol. 8(43)2017.PubMed/NCBI View Article : Google Scholar
41	MacKenzie SH, Schipper JL and Clark AC: The potential for caspases in drug discovery. Curr Opin Drug Discov Devel. 13:568–576. 2010.PubMed/NCBI
42	Ito M, Shichita T, Okada M, Komine R, Noguchi Y, Yoshimura A and Morita R: Bruton's tyrosine kinase is essential for NLRP3 inflammasome activation and contributes to ischaemic brain injury. Nat Commun. 6(7360)2015.PubMed/NCBI View Article : Google Scholar
43	Pokhrel NK, Kim YG, Kim HJ, Kim HJ, Lee JH, Choi SY, Kwon TG, Lee HJ, Kim JY and Lee Y: A novel Bruton's tyrosine kinase inhibitor, acalabrutinib, suppresses osteoclast differentiation and Porphyromonas gingivalis lipopolysaccharide-induced alveolar bone resorption. J Periodontol. 90:546–554. 2019.PubMed/NCBI View Article : Google Scholar
44	Misawa T, Takahama M, Kozaki T, Lee H, Zou J, Saitoh T and Akira S: Microtubule-driven spatial arrangement of mitochondria promotes activation of the NLRP3 inflammasome. Nat Immunol. 14:454–460. 2013.PubMed/NCBI View Article : Google Scholar
45	Aral CA, Aral K, Yay A, Özçoban Ö, Berdeli A and Saraymen R: Effects of colchicine on gingival inflammation, apoptosis, and alveolar bone loss in experimental periodontitis. J Periodontol. 89:577–585. 2018.PubMed/NCBI View Article : Google Scholar
46	Cheng R, Wu Z, Li M, Shao M and Hu T: Interleukin-1β is a potential therapeutic target for periodontitis: A narrative review. Int J Oral Sci. 12(2)2020.PubMed/NCBI View Article : Google Scholar
47	Yoshinari N, Kawase H, Mitani A, Ito M, Sugiishi S, Matsuoka M, Shirozu N, Ishihara Y, Bito B, Hiraga M, et al: Effects of scaling and root planing on the amounts of interleukin-1 and interleukin-1 receptor antagonist and the mRNA expression of interleukin-1beta in gingival crevicular fluid and gingival tissues. J Periodontal Res. 39:158–167. 2004.PubMed/NCBI View Article : Google Scholar
48	Mistry P, Reid J, Pouliquen I, McHugh S, Abberley L, DeWall S, Taylor A, Tong X, Rocha Del Cura M and McKie E: Safety, tolerability, pharmacokinetics, and pharmacodynamics of single-dose antiinterleukin-18 mAb GSK1070806 in healthy and obese subjects. Int J Clin Pharmacol Ther. 52:867–879. 2014.PubMed/NCBI View Article : Google Scholar
49	Guarda G, Braun M, Staehli F, Tardivel A, Mattmann C, Förster I, Farlik M, Decker T, Du Pasquier RA, Romero P, et al: Type I interferon inhibits interleukin-1 production and inflammasome activation. Immunity. 34:213–223. 2011.PubMed/NCBI View Article : Google Scholar
50	Rathinam VA, Vanaja SK and Fitzgerald KA: Regulation of inflammasome signaling. Nat Immunol. 13:333–342. 2012.PubMed/NCBI View Article : Google Scholar
51	Hu Y, Mao K, Zeng Y, Chen S, Tao Z, Yang C, Sun S, Wu X, Meng G and Sun B: Tripartite-motif protein 30 negatively regulates NLRP3 inflammasome activation by modulating reactive oxygen species production. J Immunol. 185:7699–7705. 2010.PubMed/NCBI View Article : Google Scholar